RATIONALE: Hyper-IgE Syndrome (HIES) is a primary immunodeficiency characterized by increased serum levels of IgE, eczematous dermatitis and skin and/or recurrent sinopulmonary infections. The objective of this study is to find if there are associations between STAT3 mutations and phenotypic features in HIES. METHODS: Thirteen patients with clinical suspicion of HIES answered a validated questionnaire proposed by WOELNER et. al. and their blood samples were collected. The samples were sequenced for STAT3 cDNA mutations. We identified mutations in the amplified exons and associated the genotype of the subjects with their clinical phenotype. RESULTS: The clinical score for HIES fluctuated from 5,83 to 56,63 (não tem unidade?) All subjects had history of severe infections and most of it was skin abscesses. Almost all of the subjects (92%) had eczematous dermatitis and IgE levels shifted from 980 to 32.415 UI/mL.. The Mutations in STAT3 were found in four patients. They were I659N, R382W, E638G and Y657C. One of the mutations, I659N, was never described in the literature before. We are now trying to understand how how this mutation would impact the phontypic features. CONCLUSIONS: The analysis included 13 patients with clinical suspicion of HIES of which only 4 presented mutation in STAT3. We did not find an associantion between STAT3 mutations and phenotypic features in the subjects with HIES. University of Utah Department of Pediatrics, Division of Hematology and Oncology, Salt Lake City, UT, 3 University of Utah, Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Salt Lake City, UT, 4 University of Utah, Department of Pediatrics, Division of Allergy and Immunology, Salt Lake City, UT. RATIONALE: The incidence of inflammatory bowel disease (IBD) in patients with chronic granulomatous disease (CGD) is as high as 50%. Typical IBD treatments come with increased risk of infection in these patients. We examined the incidence of IBD in our local CGD population to determine when and how IBD is diagnosed. METHODS: Clinical and laboratory data were collected from 10 subjects with CGD at our institution from the years 2003 to present. Patients were categorized by genetic mutations, GI symptoms, and HSCT recipients. RESULTS: Of 10 patients, 4/10 had IBD (CGD-IBD) with supportive histologic findings. Four additional patients had significant GI symptoms (CGD-GI) but were never diagnosed with IBD; two had biopsy negative findings and two never underwent diagnostic evaluation. Two CGD-IBD patients received HSCT, and both had subsequent resolution of GI symptoms. Notably, one CGD-GI patient who never underwent endoscopy had resolution of GI symptoms after HSCT. All eight CGD-IBD and CGD-GI patients had X-linked CYBB gene mutations. The remaining two patients in this cohort had autosomal recessive NCF1 mutations, and neither had GI symptoms. CONCLUSIONS: In our cohort, there was a higher incidence of IBD in patients with X-linked CGD. Patients with CGD had symptoms of IBD at the time of or even preceding diagnosis; IBD in CGD is likely underdiagnosed due to a lack of standard laboratory or endoscopy screening guidelines. HSCTwas curative for GI disease manifestations in 3/3 patients in our cohort. We previously found that adults with immunoglobulin E (IgE) deficiency (<2.5 kU/L) have higher rates of prior malignancy. We sought to investigate the relationship between malignancy and IgE deficiency in children. METHODS: We retrospectively identified children (<18 years) with IgE levels performed at our hospital between 2010-2017. Patients were categorized as IgE deficient (IgE<2.5 kU/L) vs non-IgE deficient [divided in normal IgE (2.5-100 kU/L), high IgE (100-1000 kU/L) and very high IgE (> _1000 kU/ L) levels]. Rates of malignancy diagnoses were compared between groups. RESULTS: IgE levels were measured in 4,586 children and 94 (2.0%) had IgE deficiency. The IgE deficiency group was younger (4.19 years 64.05) compared to the non-IgE deficiency cohort (7.3 years 64.5, p<0.01) and included more whites (10.6% vs. 4.4%, p<0.01). A significantly higher rate of any type of malignancy diagnoses was found in IgE deficient patients (4/ 94, 4.3%) compared to those with normal (19/1775, 1.1%; OR54.9, 95% CI:1.5-15.3, p<0.01), high (16/2059, 0.8%; OR58.6, 95% CI:2.5-28.8, p<0.01) and very high IgE levels (4/658, 0.6%; OR59.1, 95% CI:1.8-45, p<0.01; adjusted for age, gender and race). Lymphoma was the predominant malignancy in IgE deficient children (3/4, 75%). Leukemia (1/4, 25%) was the other type of neoplasia found in this group. CONCLUSIONS: In this tertiary-level hospital cohort of children, the rate of any type of malignancy diagnoses was significantly higher in IgE deficient versus non-IgE deficient children, with lymphoma being the most frequent cancer. Prospective studies are necessary to better define the relationship between IgE deficiency and malignancy in different cohorts of patients. RATIONALE: Fingolimod, a sphingosine 1-phosphate receptor modulator is approved as an oral daily therapy for relapsing -remitting multiple sclerosis (MS). It works by reducing lymphocyte egress from lymphocytes, thereby limiting their autoimmune effects in the CNS. This medication is known to causes a lymphopenia and leukopenia but its immunosuppressive potential is not well appreciated by practicing physicians. METHODS: Two women taking fingolimod for MS were referred to our immunology clinic for evaluation of hypogammaglobulinemia. Additional immune testing was initiated. The published medical literature on the immune effects of fingolimod was reviewed. RESULTS: Patient #1 was age 59 and had four separate bouts of zoster prior to starting therapy with fingolimod. She had a fifth zoster event while on the medication. Patient #2 was age 67. Neither patient had prior therapy with immunosuppressive drugs or natalizumab. The immune studies in both patients revealed lymphopenia, mild leukopenia, mild hypogammaglobulinemia, a severe CD4 lymphocytopenia (<30 mil/L absolute) and lymphocyte subset phenotypes indistinguishable from that seen in patients with advanced AIDS. Tests for HIV were negative. To date, increase in zoster infections, multiple basal cell skin cancers and 15 cases of progressive multifocal leukoencephalopathy have been reported in patients treated with fingolimod. CONCLUSIONS: Profound immune changes, especially with severe CD4 lymphocytopenia, can occur in patients on fingolimod therapy. There is a need to better define the risks for opportunistic infections and tumors treated with this medication.
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